# HyBryte (lymphoma) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/lymphoma

> HyBryte (lymphoma), sponsored by SOLIGENIX, INC. (SNGX): 6 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, year only, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | HyBryte (lymphoma) |
| Codes | SGX301 |
| Sponsor | SOLIGENIX, INC. (SNGX) https://sec-api.dev/companies/sngx/catalysts |
| Indications | early-stage ctcl, [ctcl with top-line results](https://sec-api.dev/indications/ctcl-with-top-line-results), ctcl and updated our enrollment progress to 66 patients in february of 2026 |
| Modality |  |
| FDA designations | fast track, orphan |

## Timeline

### Dec 2022: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2025-03-21, last confirmed 2025-11-07.
- SEC Form 10-Q (accession 0001104659-25-108475): "In December 2022, we submitted the HyBryte™ NDA for the treatment of CTCL with the FDA." https://www.sec.gov/Archives/edgar/data/812796/000110465925108475/sngx-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-011554): "In December 2022, we submitted the HyBryte™ NDA for the treatment of CTCL with the FDA." https://www.sec.gov/Archives/edgar/data/812796/000155837025011554/sngx-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-007171): "In December 2022, we submitted the HyBryte™ NDA for the treatment of CTCL with the FDA." https://www.sec.gov/Archives/edgar/data/812796/000155837025007171/sngx-20250331x10q.htm
- SEC Form 10-K (accession 0001558370-25-003459): "In December 2022, we submitted the HyBryte™ NDA for the treatment of CTCL with the FDA." https://www.sec.gov/Archives/edgar/data/812796/000155837025003459/sngx-20241231x10k.htm

### Apr 2023: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2025-03-21, last confirmed 2026-05-08.
- SEC Form 10-Q (accession 0001104659-26-057904): "In April 2023, we had a Type A meeting with the FDA to clarify and respond to the issues identified in the RTF letter received from the FDA and to seek additional guidance concerning information that the FDA would require for a resubmitted NDA to be deemed acceptable to file, in order to advance HyBryte™ towards marketing approval and U.S. commercialization." https://www.sec.gov/Archives/edgar/data/812796/000110465926057904/sngx-20260331x10q.htm
- SEC Form 10-K (accession 0001104659-26-037701): "In April 2023, we had a Type A meeting with the FDA to clarify and respond to the issues identified in the RTF letter received from the FDA and to seek additional guidance concerning information that the FDA would require for a resubmitted NDA to be deemed acceptable to file, in order to advance HyBryte™ towards marketing approval and U.S. commercialization." https://www.sec.gov/Archives/edgar/data/812796/000110465926037701/sngx-20251231x10k.htm
- SEC Form 10-Q (accession 0001104659-25-108475): "In April 2023, we had a Type A meeting with the FDA to clarify and respond to the issues identified in the RTF letter received from the FDA and to seek additional guidance concerning information that the FDA would require for a resubmitted NDA to be deemed acceptable to file, in order to advance HyBryte™ towards marketing approval and U.S. commercialization." https://www.sec.gov/Archives/edgar/data/812796/000110465925108475/sngx-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-011554): "In April 2023, we had a Type A meeting with the FDA to clarify and respond to the issues identified in the RTF letter received from the FDA and to seek additional guidance concerning information that the FDA would require for a resubmitted NDA to be deemed acceptable to file, in order to advance HyBryte™ towards marketing approval and U.S. commercialization." https://www.sec.gov/Archives/edgar/data/812796/000155837025011554/sngx-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-007171): "In April 2023, we had a Type A meeting with the FDA to clarify and respond to the issues identified in the RTF letter received from the FDA and to seek additional guidance concerning information that the FDA would require for a resubmitted NDA to be deemed acceptable to file, in order to advance HyBryte™ towards marketing approval and U.S. commercialization." https://www.sec.gov/Archives/edgar/data/812796/000155837025007171/sngx-20250331x10q.htm
- SEC Form 10-K (accession 0001558370-25-003459): "In April 2023, we had a Type A meeting with the FDA to clarify and respond to the issues identified in the RTF letter received from the FDA and to seek additional guidance concerning information that the FDA would require for a resubmitted NDA to be deemed acceptable to file, in order to advance HyBryte™ towards marketing approval and U.S. commercialization." https://www.sec.gov/Archives/edgar/data/812796/000155837025003459/sngx-20241231x10k.htm

### Apr 2025: interim data readout

- Status: completed, positive. Date confidence: month. Indication: early-stage CTCL.
- First seen 2025-08-14, last confirmed 2026-05-08.
- SEC Form 10-Q (accession 0001104659-26-057904): "In April 2025, we announced positive interim results from the ongoing open-label, IIS evaluating extended HyBryte™ treatment for up to 54 weeks in patients with early-stage CTCL." https://www.sec.gov/Archives/edgar/data/812796/000110465926057904/sngx-20260331x10q.htm
- SEC Form 10-K (accession 0001104659-26-037701): "In April 2025, we announced positive interim results from the ongoing open-label, IIS evaluating extended HyBryte™ treatment for up to 54 weeks in patients with early-stage CTCL." https://www.sec.gov/Archives/edgar/data/812796/000110465926037701/sngx-20251231x10k.htm
- SEC Form 10-Q (accession 0001104659-25-108475): "In April 2025, we announced positive interim results from the ongoing open-label, IIS evaluating extended HyBryte™ treatment for up to 54 weeks in patients with early-stage CTCL." https://www.sec.gov/Archives/edgar/data/812796/000110465925108475/sngx-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-011554): "In April 2025, we announced positive interim results from the ongoing open-label, IIS evaluating extended HyBryte™ treatment for up to 54 weeks in patients with early-stage CTCL." https://www.sec.gov/Archives/edgar/data/812796/000155837025011554/sngx-20250630x10q.htm

### 2026: trial start

- Status: scheduled. Date confidence: year.
- First seen 2026-03-18, last confirmed 2026-03-18.
- SEC Form 10-K (accession 0001104659-26-031274): "Furthermore, in anticipation of the commencement of our larger pivotal trial for Lymphoma in 2026, as well as the eventual need for commercial scale production, we intend to evaluate and qualify additional potential third-party manufacturing partners to provide potential multiple sources of clinical and commercial supply." https://www.sec.gov/Archives/edgar/data/1094038/000110465926031274/mrkr-20251231x10k.htm

### Q2 2026: interim data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: CTCL and updated our enrollment progress to 66 patients in February of 2026.
- First seen 2026-03-31, last confirmed 2026-03-31.
- SEC Form 10-K (accession 0001104659-26-037701): "In November 2025, we successfully completed the planned enrollment of 50 patients necessary for the planned interim analysis in the second quarter of 2026 for our confirmatory Phase 3 study evaluating HyBryte™ in the treatment of CTCL and updated our enrollment progress to 66 patients in February of 2026." https://www.sec.gov/Archives/edgar/data/812796/000110465926037701/sngx-20251231x10k.htm

### 2H 2026: topline data readout

- Status: scheduled. Date confidence: half. Stage: 3. Indication: CTCL with top-line results.
- First seen 2026-03-31, last confirmed 2026-05-08.
- SEC Form 10-Q (accession 0001104659-26-057904): "In December 2024, we opened patient enrollment for our confirmatory Phase 3 study evaluating HyBryte™ (synthetic hypericin) in the treatment of CTCL with top-line results anticipated in the second half of 2026." https://www.sec.gov/Archives/edgar/data/812796/000110465926057904/sngx-20260331x10q.htm
- SEC Form 10-K (accession 0001104659-26-037701): "In December 2024, we opened patient enrollment for our confirmatory Phase 3 study evaluating HyBryte™ (synthetic hypericin) in the treatment of CTCL with top-line results anticipated in the second half of 2026." https://www.sec.gov/Archives/edgar/data/812796/000110465926037701/sngx-20251231x10k.htm
- SEC Form 10-K (accession 0001104659-26-037701): "We anticipate top-line results in the second half of 2026." https://www.sec.gov/Archives/edgar/data/812796/000110465926037701/sngx-20251231x10k.htm

## Same indication

- [Hypericin](https://sec-api.dev/pdufa/hypericin) (SNGX)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/lymphoma.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "HyBryte (lymphoma) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/lymphoma

```bibtex
@misc{secapidev_pdufa_lymphoma_20261116,
  title        = {HyBryte (lymphoma) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/lymphoma}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_lymphoma_20261116","title":"HyBryte (lymphoma) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/lymphoma","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
